Skip to main content
Top
Published in: Endocrine 2/2015

01-03-2015 | Original Article

Basis of aggravated hepatic lipid metabolism by chronic stress in high-fat diet-fed rat

Authors: Ying Han, Min Lin, Xiaobin Wang, Keke Guo, Shanshan Wang, Mengfei Sun, Jiao Wang, Xiaoyu Han, Ting Fu, Yang Hu, Jihua Fu

Published in: Endocrine | Issue 2/2015

Login to get access

Abstract

Our previous study has demonstrated that long-term stress, known as chronic stress (CS), can aggravate nonalcoholic fatty liver disease in high-fat diet (HFD)-fed rat. In this study, we tried to figure out which lipid metabolic pathways were impacted by CS in the HFD-fed rat. Male Sprague–Dawley rats (6 weeks of age, n = 8 per group) were fed with either standard diet or HFD with or without CS exposure for 8 weeks. Hepatic lipidosis, biochemical, hormonal, and lipid profile markers in serum and liver, and enzymes involved in de novo lipogenesis (DNL) of fatty acids (FAs) and cholesterol, β-oxidation, FAs uptake, triglycerides synthesis, and very low-density lipoprotein (VLDL) assembly in the liver were detected. CS exposure reduced hepatic lipidosis but further elevated hepatic VLDL content with aggravated dyslipidemia in the HFD-fed rats. There was a synergism between CS and HFD on VLDL production and dyslipidemia. PCR and western blot assays showed that CS exposure significantly promoted hepatic VLDL assembly in rats, especially in the HFD-fed rats, while it had little impact on DNL, β-oxidation, FAs uptake, and triglycerides synthesis in the HFD-fed rats. This phenomenon was in accordance with elevated serum glucocorticoid level. The critical influence of CS exposure on hepatic lipid metabolism in the HFD-fed rats is VLDL assembly which might be regulated by glucocorticoid.
Literature
1.
go back to reference J.A. Marrero, R.J. Fontana, G.L. Su et al., NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 36(6), 1349–1354 (2002)CrossRefPubMed J.A. Marrero, R.J. Fontana, G.L. Su et al., NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 36(6), 1349–1354 (2002)CrossRefPubMed
2.
go back to reference G. Marchesini, M. Brizi, A.M. Morselli-Labate et al., Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med. 107, 450–455 (1999)CrossRefPubMed G. Marchesini, M. Brizi, A.M. Morselli-Labate et al., Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med. 107, 450–455 (1999)CrossRefPubMed
3.
go back to reference M.M. Yeh, E.M. Brunt, Pathology of nonalcoholic fatty liver disease. Am. J. Clin. Pathol. 128, 837–847 (2007)CrossRefPubMed M.M. Yeh, E.M. Brunt, Pathology of nonalcoholic fatty liver disease. Am. J. Clin. Pathol. 128, 837–847 (2007)CrossRefPubMed
4.
5.
go back to reference B.M. Tannenbaum, D.N. Brindley, G.S. Tannenbaum et al., High-fat feeding alters both basal and stress-induced hypothalamic– pituitary–adrenal activity in the rat. Am. J. Physiol. 273(6 Pt 1), E1168–E1177 (1997)PubMed B.M. Tannenbaum, D.N. Brindley, G.S. Tannenbaum et al., High-fat feeding alters both basal and stress-induced hypothalamic– pituitary–adrenal activity in the rat. Am. J. Physiol. 273(6 Pt 1), E1168–E1177 (1997)PubMed
6.
go back to reference J.H. Fu, S.R. Xie, S.J. Kong et al., The combination of a high-fat diet and chronic stress aggravates insulin resistance in Wistar male rats. Exp. Clin. Endocrinol. Diabetes 117(7), 354–360 (2009)CrossRefPubMed J.H. Fu, S.R. Xie, S.J. Kong et al., The combination of a high-fat diet and chronic stress aggravates insulin resistance in Wistar male rats. Exp. Clin. Endocrinol. Diabetes 117(7), 354–360 (2009)CrossRefPubMed
7.
go back to reference G. Musso, R. Gambino, M. Cassader, Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog. Lipid Res. 48(1), 1–26 (2009)CrossRefPubMed G. Musso, R. Gambino, M. Cassader, Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog. Lipid Res. 48(1), 1–26 (2009)CrossRefPubMed
8.
go back to reference P. Nguyen, V. Leray, M. Diez et al., Liver lipid metabolism. J Anim Physiol Anim Nutr (Berl) 92(3), 272–283 (2008)CrossRef P. Nguyen, V. Leray, M. Diez et al., Liver lipid metabolism. J Anim Physiol Anim Nutr (Berl) 92(3), 272–283 (2008)CrossRef
9.
go back to reference D.P. Macfarlane, S. Forbes, B.R. Walker, Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome. J. Endocrinol. 197, 189–204 (2008)CrossRefPubMed D.P. Macfarlane, S. Forbes, B.R. Walker, Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome. J. Endocrinol. 197, 189–204 (2008)CrossRefPubMed
10.
go back to reference J.H. Fu, H.S. Sun, Y. Wang et al., The effects of a fat- and sugar-enriched diet and chronic stress on nonalcoholic fatty liver disease in male Wistar rats. Dig. Dis. Sci. 55(8), 2227–2236 (2010)CrossRefPubMed J.H. Fu, H.S. Sun, Y. Wang et al., The effects of a fat- and sugar-enriched diet and chronic stress on nonalcoholic fatty liver disease in male Wistar rats. Dig. Dis. Sci. 55(8), 2227–2236 (2010)CrossRefPubMed
11.
go back to reference S. Gao, X. Han, J. Fu et al., Influence of chronic stress on the compositions of hepatic cholesterol and triglyceride in male Wistar rats fed a high fat diet. Hepatol. Res. 42(7), 686–695 (2012)CrossRefPubMed S. Gao, X. Han, J. Fu et al., Influence of chronic stress on the compositions of hepatic cholesterol and triglyceride in male Wistar rats fed a high fat diet. Hepatol. Res. 42(7), 686–695 (2012)CrossRefPubMed
12.
go back to reference S.M. Haffner, E. Kennedy, C. Gonzalez et al., A prospective analysis of the HOMA model. The Mexico City Diabetes Study. Diabetes Care 19, 1138–1141 (1996)CrossRefPubMed S.M. Haffner, E. Kennedy, C. Gonzalez et al., A prospective analysis of the HOMA model. The Mexico City Diabetes Study. Diabetes Care 19, 1138–1141 (1996)CrossRefPubMed
13.
go back to reference D.E. Kleiner, E.M. Brunt, M. Van Natta et al., Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41(6), 1313–1321 (2005)CrossRefPubMed D.E. Kleiner, E.M. Brunt, M. Van Natta et al., Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41(6), 1313–1321 (2005)CrossRefPubMed
14.
go back to reference R.S. Kukreja, B.N. Datta, R.N. Chakravarti, Catecholamine-induced aggravation of aortic and coronary atherosclerosis in monkeys. Atherosclerosis 40, 291–298 (1981)CrossRefPubMed R.S. Kukreja, B.N. Datta, R.N. Chakravarti, Catecholamine-induced aggravation of aortic and coronary atherosclerosis in monkeys. Atherosclerosis 40, 291–298 (1981)CrossRefPubMed
15.
go back to reference E. Kitrakia, G. Soulisa, K. Gerozissisb, Impaired neuroendocrine response to stress following a short-term fat-enriched diet. Neuroendocrinology 79, 338–345 (2004)CrossRef E. Kitrakia, G. Soulisa, K. Gerozissisb, Impaired neuroendocrine response to stress following a short-term fat-enriched diet. Neuroendocrinology 79, 338–345 (2004)CrossRef
16.
go back to reference A. Legendre, B.S. Ruth, Exaggerated response to mild stress in rats fed high-fat diet. Am. J. Physiol. Regul. Integr. Comp. Physiol. 291, 1288–1294 (2006)CrossRef A. Legendre, B.S. Ruth, Exaggerated response to mild stress in rats fed high-fat diet. Am. J. Physiol. Regul. Integr. Comp. Physiol. 291, 1288–1294 (2006)CrossRef
17.
go back to reference R. Collu, Y. Taché, J.R. Ducharme, Hormonal modifications induced by chronic stress in rats. J. Steroid. Biochem. 11(1C), 989–1000 (1979)CrossRefPubMed R. Collu, Y. Taché, J.R. Ducharme, Hormonal modifications induced by chronic stress in rats. J. Steroid. Biochem. 11(1C), 989–1000 (1979)CrossRefPubMed
18.
go back to reference L.A. Adams, A. Feldstein, K.D. Lindor et al., Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology 39, 909–914 (2004)CrossRefPubMed L.A. Adams, A. Feldstein, K.D. Lindor et al., Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology 39, 909–914 (2004)CrossRefPubMed
19.
go back to reference D.K. Bloomfield, Dynamics of cholesterol metabolism. I. Factors regulating total sterol biosynthesis and accumulation in the rat. Proc. Natl. Acad. Sci. USA 50, 117–124 (1963)CrossRefPubMedCentralPubMed D.K. Bloomfield, Dynamics of cholesterol metabolism. I. Factors regulating total sterol biosynthesis and accumulation in the rat. Proc. Natl. Acad. Sci. USA 50, 117–124 (1963)CrossRefPubMedCentralPubMed
20.
go back to reference F. Foufelle, P. Ferré, New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c. Biochem. J. 366(Pt 2), 377–391 (2002)CrossRefPubMedCentralPubMed F. Foufelle, P. Ferré, New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c. Biochem. J. 366(Pt 2), 377–391 (2002)CrossRefPubMedCentralPubMed
21.
go back to reference H.S. Sul, D. Wang, Nutritional and hormonal regulation of enzymes in fat synthesis: studies of fatty acid synthase and mitochondrial glycerol-3-phosphate acyltransferase gene transcription. Annu. Rev. Nutr. 18, 331–351 (1998)CrossRefPubMed H.S. Sul, D. Wang, Nutritional and hormonal regulation of enzymes in fat synthesis: studies of fatty acid synthase and mitochondrial glycerol-3-phosphate acyltransferase gene transcription. Annu. Rev. Nutr. 18, 331–351 (1998)CrossRefPubMed
22.
go back to reference L.S. Sidossis, B. Mittendorfer, E. Walser et al., Hyperglycemia-induced inhibition of splanchnic fatty acid oxidation increases hepatic triacylglycerol secretion. Am. J. Physiol. 275(5 Pt 1), E798–E805 (1998)PubMed L.S. Sidossis, B. Mittendorfer, E. Walser et al., Hyperglycemia-induced inhibition of splanchnic fatty acid oxidation increases hepatic triacylglycerol secretion. Am. J. Physiol. 275(5 Pt 1), E798–E805 (1998)PubMed
23.
go back to reference B. Hubbard, H. Doege, S. Punreddy et al., Mice deleted for fatty acid transport protein 5 have defective bile acid conjugation and are protected from obesity. Gastroenterology 130(4), 1259–1269 (2006)CrossRefPubMed B. Hubbard, H. Doege, S. Punreddy et al., Mice deleted for fatty acid transport protein 5 have defective bile acid conjugation and are protected from obesity. Gastroenterology 130(4), 1259–1269 (2006)CrossRefPubMed
24.
go back to reference M. Schreurs, F. Kuipers, F.R. van der Leij, Regulatory enzymes of mitochondrial beta-oxidation as targets for treatment of the metabolic syndrome. Obes. Rev. 11(5), 380–388 (2010)CrossRefPubMed M. Schreurs, F. Kuipers, F.R. van der Leij, Regulatory enzymes of mitochondrial beta-oxidation as targets for treatment of the metabolic syndrome. Obes. Rev. 11(5), 380–388 (2010)CrossRefPubMed
25.
go back to reference L. Yang, Y. Zhang, S. Wang et al., Decreased liver peroxisomal β-oxidation accompanied by changes in brain fatty acid composition in aged rats. Neurol Sci. 35(2), 289–293 (2014)CrossRefPubMed L. Yang, Y. Zhang, S. Wang et al., Decreased liver peroxisomal β-oxidation accompanied by changes in brain fatty acid composition in aged rats. Neurol Sci. 35(2), 289–293 (2014)CrossRefPubMed
26.
go back to reference M. Zhou, E.A. Fisher, H.N. Ginsberg, Regulated co-translational ubiquitination of apoliprotein B100. A new paradigm for proteasomal degradation of a secretory protein. J. Biol. Chem. 273, 24649–24653 (1998)CrossRefPubMed M. Zhou, E.A. Fisher, H.N. Ginsberg, Regulated co-translational ubiquitination of apoliprotein B100. A new paradigm for proteasomal degradation of a secretory protein. J. Biol. Chem. 273, 24649–24653 (1998)CrossRefPubMed
27.
go back to reference R.A. Davis, Cell and molecular biology of the assembly and secretion of apolipoprotein B-containing lipoproteins by the liver. Biochim. Biophys. Acta 1440(1), 1–31 (1999)CrossRefPubMed R.A. Davis, Cell and molecular biology of the assembly and secretion of apolipoprotein B-containing lipoproteins by the liver. Biochim. Biophys. Acta 1440(1), 1–31 (1999)CrossRefPubMed
28.
go back to reference E.A. Fisher, The degradation of apolipoprotein B100: Multiple opportunities to regulate VLDL triglyceride production by different proteolytic pathways. Biochim. Biophys. Acta 1821(5), 778–781 (2012)CrossRefPubMedCentralPubMed E.A. Fisher, The degradation of apolipoprotein B100: Multiple opportunities to regulate VLDL triglyceride production by different proteolytic pathways. Biochim. Biophys. Acta 1821(5), 778–781 (2012)CrossRefPubMedCentralPubMed
29.
go back to reference C.C. Chang, N. Sakashita, K. Ornvold et al., Immunological quantitation and localization of ACAT-1 and ACAT-2 in human liver and small intestine. J. Biol. Chem. 275(36), 28083–28092 (2000)PubMed C.C. Chang, N. Sakashita, K. Ornvold et al., Immunological quantitation and localization of ACAT-1 and ACAT-2 in human liver and small intestine. J. Biol. Chem. 275(36), 28083–28092 (2000)PubMed
30.
go back to reference C. Leon, J.S. Hill, K.M. Wasan, Potential role of acyl-coenzyme A: cholesterol transferase (ACAT) Inhibitors as hypolipidemic and antiatherosclerosis drugs. Pharm. Res. 22(10), 1578–1588 (2005)CrossRefPubMed C. Leon, J.S. Hill, K.M. Wasan, Potential role of acyl-coenzyme A: cholesterol transferase (ACAT) Inhibitors as hypolipidemic and antiatherosclerosis drugs. Pharm. Res. 22(10), 1578–1588 (2005)CrossRefPubMed
31.
go back to reference L.J. Wilcox, N.M. Borradaile, L.E. de Dreu et al., Secretion of hepatocyte apoB is inhibited by the flavonoids, naringenin and hesperetin, via reduced activity and expression of ACAT2 and MTTP. J. Lipid Res. 42(5), 725–734 (2001)PubMed L.J. Wilcox, N.M. Borradaile, L.E. de Dreu et al., Secretion of hepatocyte apoB is inhibited by the flavonoids, naringenin and hesperetin, via reduced activity and expression of ACAT2 and MTTP. J. Lipid Res. 42(5), 725–734 (2001)PubMed
32.
go back to reference E.A. Fisher, M. Pan, X. Chen et al., The triple threat to nascent apolipoprotein B. Evidence for multiple, distinct degradative pathways. J. Biol. Chem. 276, 27855–27863 (2001)CrossRefPubMed E.A. Fisher, M. Pan, X. Chen et al., The triple threat to nascent apolipoprotein B. Evidence for multiple, distinct degradative pathways. J. Biol. Chem. 276, 27855–27863 (2001)CrossRefPubMed
33.
go back to reference B. Fromenty, Fat accretion in a subpopulation of hepatocytes as a strategy to protect the whole liver against oxidative stress and lipotoxicity. Clin. Res. Hepatol. Gastroenterol. 37(6), 553–555 (2013)CrossRefPubMed B. Fromenty, Fat accretion in a subpopulation of hepatocytes as a strategy to protect the whole liver against oxidative stress and lipotoxicity. Clin. Res. Hepatol. Gastroenterol. 37(6), 553–555 (2013)CrossRefPubMed
34.
go back to reference C.N. Wang, R.S. McLeod, Z. Yao et al., Effects of dexamethasone on the synthesis, degradation, and secretion of apolipoprotein B in cultured rat hepatocytes. Arterioscler. Thromb. Vasc. Biol. 15(9), 1481–1491 (1995)CrossRefPubMed C.N. Wang, R.S. McLeod, Z. Yao et al., Effects of dexamethasone on the synthesis, degradation, and secretion of apolipoprotein B in cultured rat hepatocytes. Arterioscler. Thromb. Vasc. Biol. 15(9), 1481–1491 (1995)CrossRefPubMed
35.
go back to reference M. Devaki, R. Nirupama, H.N. Yajurvedi, Chronic stress-induced oxidative damage and hyperlipidemia are accompanied by atherosclerotic development in rats. Stress 16(2), 233–243 (2013)CrossRefPubMed M. Devaki, R. Nirupama, H.N. Yajurvedi, Chronic stress-induced oxidative damage and hyperlipidemia are accompanied by atherosclerotic development in rats. Stress 16(2), 233–243 (2013)CrossRefPubMed
Metadata
Title
Basis of aggravated hepatic lipid metabolism by chronic stress in high-fat diet-fed rat
Authors
Ying Han
Min Lin
Xiaobin Wang
Keke Guo
Shanshan Wang
Mengfei Sun
Jiao Wang
Xiaoyu Han
Ting Fu
Yang Hu
Jihua Fu
Publication date
01-03-2015
Publisher
Springer US
Published in
Endocrine / Issue 2/2015
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-014-0307-x

Other articles of this Issue 2/2015

Endocrine 2/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.